SCHEMBL4052795

SCHEMBL4052795

c1coc(-c2cnc3nc(CCC4CCCC4)[nH]c3c2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 2/20 0.39
NOS1 P29475 2/20 0.39
NOS2 P35228 2/20 0.39
CHRNB1 P11230 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNB3 Q05901 1/20 0.36
CCNA2 P20248 1/20 0.35
CDK2 P24941 1/20 0.35
CCNA1 P78396 1/20 0.35
ADORA2A P29274 4/20 0.35
ADORA1 P30542 4/20 0.35
ADORA2B P29275 2/20 0.35
AAK1 Q2M2I8 1/20 0.34
ADORA3 P0DMS8 3/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
USP30 Q70CQ3 1/20 0.33
BRS3 P32247 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4055947 0.83 NOS3 (0.53) NOS3NOS1NOS2CDK2AAK1
SCHEMBL13608028 0.83 ADORA2A (0.37) CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3
SCHEMBL4060650 0.80 NOS3 (0.49) NOS3NOS1NOS2ADORA2AADORA1
SCHEMBL4055566 0.78 SCD (0.41) NOS3NOS1NOS2AAK1USP30
SCHEMBL4056184 0.77 NOS3 (0.41) NOS3NOS1NOS2CHRNB1CHRNB2
SCHEMBL4054509 0.77 USP30 (0.47) ADORA2AADORA1ADORA2BADORA3USP30
SCHEMBL4053237 0.77 NOS3 (0.42) NOS3NOS1NOS2ADORA2AADORA1
SCHEMBL4057778 0.77 NOS3 (0.44) NOS3NOS1NOS2ADORA2AADORA1
SCHEMBL4058313 0.77 NOS1 (0.44) NOS3NOS1NOS2ADORA2AADORA1
SCHEMBL4054880 0.77 NOS3 (0.42) NOS3NOS1NOS2ADORA2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NOS3 907/4885NOS1 879/4885NOS2 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.